The acquisition is a strategic bolt-on that diversifies argenx's immunology platform beyond FcRn into T-cell/NK-cell biology with early clinical validation. Watch for HSR clearance and tender results in Q3; Phase 2 celiac data in H2 2026 is the next major catalyst for FB102. The all-cash structure removes financing risk, and the premium reflects argenx's conviction in FB102's pipeline-in-a-product potential.
Price Chart
Executive Summary
argenx is acquiring Forte Biosciences for $77/share in cash, total equity value ~$2.2B, an 86% premium to Forte's VWAP since positive Phase 1b vitiligo data. The deal adds FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease, fitting argenx's strategy to expand its immunology pipeline beyond FcRn blockade. The acquisition is fully funded from cash on hand and expected to close in Q3 2026, with no financing condition — a disciplined bolt-on that broadens argenx's T-cell/NK-cell targeting capability without diluting shareholders.
Key Financial Metrics
Key Facts
- argenx acquires Forte Biosciences for $77/share cash, ~$2.2B total equity value
- 86% premium to Forte's VWAP since July 9, 2026 positive Phase 1b vitiligo data
- FB102 is a first-in-class anti-CD122 antibody with Phase 1b proof-of-concept in vitiligo and celiac disease
- Phase 2 celiac data expected H2 2026; potential in alopecia areata and other autoimmune diseases
- Transaction fully funded from cash on hand, no financing condition
- Expected to close in Q3 2026, subject to HSR and tender of majority of shares
- Goldman Sachs and Freshfields advising argenx; Guggenheim and Wilson Sonsini advising Forte
Financial Impact
$2.2 billion total equity value at $77/share cash, 86% premium to unaffected VWAP
Risk Factors
- HSR antitrust review could delay or impose conditions
- Phase 2 celiac data may not replicate Phase 1b results
- Integration risk and potential distraction from core efgartigimod franchise
- Competition from other T-cell targeting therapies in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3333257 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Institutional Cluster | $984.04 $995.77 | ▲ +1.19% | ▲ +1.69% | $918.23 (−6.69%) |
Aug 17, 2026 6w ago | 6-K | $987.84 $1,011.11 | ▲ +2.36% | ▲ +3.55% | $918.23 (−7.05%) |
Aug 6, 2026 8w ago | Press Release | $875.30 $856.94 | ▼ −2.10% | ▼ −3.31% | $918.23 (+4.91%) |
Jul 27, 2026 9w ago | 6-K | $888.82 $853.82 | ▼ −3.94% | ▼ −5.01% | $918.23 (+3.31%) |
Jul 27, 2026 9w ago | Press Release | $888.82 $853.82 | ▼ −3.94% | ▼ −5.01% | $918.23 (+3.31%) |
Jul 23, 2026 10w ago | Press Release | $924.60 $872.58 | ▼ −5.63% | ▼ −6.10% | $918.23 (−0.69%) |
Jul 16, 2026 11w ago | Press Release | $857.97 $924.60 | ▲ +7.77% | ▲ +9.44% | $918.23 (+7.02%) |
Jun 23, 2026 14w ago | 6-K | $853.40 $912.46 | ▲ +6.92% | ▲ +5.91% | $918.23 (+7.60%) |
Jun 3, 2026 17w ago | 6-K | $813.14 $862.18 | ▲ +6.03% | ▲ +9.85% | $918.23 (+12.92%) |
May 8, 2026 20w ago | Press Release | $813.28 $776.26 | ▼ −4.55% | ▼ −4.47% | $918.23 (+12.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access